Last reviewed · How we verify

Fenretinide Lym-X-Sorb Oral Powder

South Plains Oncology Consortium · Phase 2 active Small molecule

Fenretinide Lym-X-Sorb Oral Powder is a retinoid Small molecule drug developed by South Plains Oncology Consortium. It is currently in Phase 2 development for Metastatic breast cancer. Also known as: 4-HPR, Fenretinide, 4-HPR/LXS, Fenretinide/LXS.

Fenretinide is a synthetic retinoid that induces apoptosis in cancer cells.

Fenretinide is a synthetic retinoid that induces apoptosis in cancer cells. Used for Metastatic breast cancer.

At a glance

Generic nameFenretinide Lym-X-Sorb Oral Powder
Also known as4-HPR, Fenretinide, 4-HPR/LXS, Fenretinide/LXS
SponsorSouth Plains Oncology Consortium
Drug classretinoid
Targetretinoic acid receptor
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Fenretinide works by activating retinoic acid receptors, which leads to the induction of apoptosis in cancer cells. This process is thought to be mediated by the activation of caspases and the disruption of mitochondrial function.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fenretinide Lym-X-Sorb Oral Powder

What is Fenretinide Lym-X-Sorb Oral Powder?

Fenretinide Lym-X-Sorb Oral Powder is a retinoid drug developed by South Plains Oncology Consortium, indicated for Metastatic breast cancer.

How does Fenretinide Lym-X-Sorb Oral Powder work?

Fenretinide is a synthetic retinoid that induces apoptosis in cancer cells.

What is Fenretinide Lym-X-Sorb Oral Powder used for?

Fenretinide Lym-X-Sorb Oral Powder is indicated for Metastatic breast cancer.

Who makes Fenretinide Lym-X-Sorb Oral Powder?

Fenretinide Lym-X-Sorb Oral Powder is developed by South Plains Oncology Consortium (see full South Plains Oncology Consortium pipeline at /company/south-plains-oncology-consortium).

Is Fenretinide Lym-X-Sorb Oral Powder also known as anything else?

Fenretinide Lym-X-Sorb Oral Powder is also known as 4-HPR, Fenretinide, 4-HPR/LXS, Fenretinide/LXS.

What drug class is Fenretinide Lym-X-Sorb Oral Powder in?

Fenretinide Lym-X-Sorb Oral Powder belongs to the retinoid class. See all retinoid drugs at /class/retinoid.

What development phase is Fenretinide Lym-X-Sorb Oral Powder in?

Fenretinide Lym-X-Sorb Oral Powder is in Phase 2.

What are the side effects of Fenretinide Lym-X-Sorb Oral Powder?

Common side effects of Fenretinide Lym-X-Sorb Oral Powder include Nausea, Vomiting, Fatigue.

What does Fenretinide Lym-X-Sorb Oral Powder target?

Fenretinide Lym-X-Sorb Oral Powder targets retinoic acid receptor and is a retinoid.

Related